Should You Buy Horizon Therapeutics PLC (HZNP) Stock Tuesday?
Tuesday, September 21, 2021 01:12 PM | InvestorsObserver Analysts
Mentioned in this article
Horizon Therapeutics PLC (HZNP) receives a strong valuation score of 71 from InvestorsObserver analysis. Our proprietary scoring system considers the overall health of the company by looking at the stock's price, earnings, and growth rate to determine if it represents a good value. HZNP holds a better value than 71% of stocks at its current price. Investors who are focused on long-term growth through buy-and-hold investing will find the Valuation Rank especially relevant when allocating their assets.
HZNP gets a 71 Valuation Rank today. Find out what this means to you and get the rest of the rankings on HZNP!
HZNP's trailing-12-month Price to Earnings (PE) ratio of 47.2 puts it above the historical average of roughly 15. HZNP is a poor value at its current trading price as investors are paying more than what its worth in relation to the company's earnings. HZNP's trailing-12-month earnings per share (EPS) of 2.29 does not justify what it is currently trading at in the market. Trailing PE ratios, however, do not factor in a company's projected growth rate, resulting in some firms having high PE ratios due to high growth potentially enticing investors even if current earnings are low.
HZNP's 12-month-forward PE to Growth (PEG) ratio of 1.57 is considered a poor value as the market is overvaluing HZNP in relation to the company's projected earnings growth due. HZNP's PEG comes from its forward price to earnings ratio being divided by its growth rate. A PEG ratio of 1 represents a perfect correlation between earnings growth and share price. Due to their incorporation of more fundamentals of a company's overall health and focusing on the future rather than the past, PEG ratios are one of the most used valuation metrics by analysts today.
